- Home
- CODA vs UNCY Comparison
CODA vs UNCY Comparison
Compare CODA & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CODA | UNCY |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.4M | 145.3M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CODA | UNCY |
|---|---|---|
| Price | $12.62 | $7.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 84.7K | ★ 657.7K |
| Earning Date | 06-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.62 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $20,316,161.00 | $675,000.00 |
| Revenue This Year | $18.28 | N/A |
| Revenue Next Year | $12.62 | $582.86 |
| P/E Ratio | $160.25 | ★ N/A |
| Revenue Growth | ★ 4.98 | N/A |
| 52 Week Low | $5.98 | $0.47 |
| 52 Week High | $18.00 | $8.74 |
Technical Indicators
Market Signals| Indicator | CODA | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 58.77 | 45.44 |
| Support Level | $10.85 | $7.05 |
| Resistance Level | $13.73 | $7.78 |
| Average True Range (ATR) | 0.48 | 0.51 |
| MACD | 0.16 | -0.15 |
| Stochastic Oscillator | 73.40 | 21.62 |
Price Performance
Historical ComparisonAbout CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.